AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
A histology-based artificial intelligence (AI) biomarker may help personalize adjuvant chemotherapy selection for patients with resected pancreatic ductal adenocarcinoma, according to the results of a study by Beaufils et al. The investigators developed and validated a deep learning model that analyzes routine histology slides to predict the relative benefit of adjuvant gemcitabine vs modified FOLFIRINOX (mFOLFIRINOX). The resulting biomarker, termed PANCprAId, identified patient subgroups with differential benefit from the two regimens in an external validation cohort from the randomized phase III PRODIGE-24/CCTG PA6 trial. The study is published in the Journal of Clinical Oncology.
NIH-Funded International Research Yields Patient-Derived Tumor Compendium
A research project funded by the National Institutes of Health (NIH), with collaborators around the country and the world, has generated extensive and diverse collections of patient-derived tumor models. Tumor tissue from patients with cancer contributed to the compendium of tumor models that will enhance the study of tumor biology and be an asset in accelerating the development of cancer therapies, while guiding future research directions.
Stanford Appoints New Leader to Expand Impact in Early Drug Development
Pamela Munster, MD, joined the Stanford Cancer Institute as the inaugural Associate Director for Early Detection and Interception Research on August 1, 2026. She also assumed a faculty appointment as a Professor in the Stanford Medicine Division of Oncology.
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
In a phase Ib study published in the Journal of Clinical Oncology, Zhao et al found that the first-in-class bispecific antibody-drug conjugate (ADC) izalontamab brengitecan (iza-bren, BL-B01D1) demonstrated antitumor activity in patients with relapsed extensive-stage small cell lung cancer, particularly when used as second-line therapy.
Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care
Above 80% of cancer care providers globally report a lack of knowledge regarding integrative oncology treatments that prevent them from offering these services to patients, according to survey findings published in Supportive Care in Cancer.
Charles Bennett and colleagues: The Inflation Reduction Act and Ibrutinib
Derek Raghavan: How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
Narjust Florez and Coral Olazagasti: Silence Is Complicity
Robert Peter Gale: Therapy With a TKI for EGFR-Variant Lung Adenocarcinoma: Lessons From CML?
Raj Mohan on Kindness, Mercy, Empathy, Compassion: Are They Relevant in the Era of Robotics and AI?
Sponsored Content
SPONSORED BY LILLY MEDICAL AFFAIRS
Treatment Considerations for Relapsed/Refractory CLL in the Post-cBTKi SettingMore Top Stories
Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth
Maura L. Gillison, MD, PhD Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything about her as a scientist, a clinician, and a person. She was direct...
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Single-agent rezatapopt produced “very deep and durable responses” in heavily pretreated patients with TP53 Y220C–mutated advanced ovarian cancer, according to updated results from the pivotal phase II PYNNACLE trial presented at the 2026 ASCO Breakthrough meeting in Singapore. The analysis was...
ASCO Publishes First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
A panel of ASCO experts voted to approve ASCO’s first guideline on ctDNA testing in patients with solid tumors or lymphoma on November 18, 2025.1 The guideline addresses four overarching clinical questions: when ctDNA testing should (or should not) be used to (1) support cancer diagnosis; (2)...
The Fear of Having Cancer Never Goes Away
There is a strong history of breast cancer in my family, and the fact that I have dense breasts adding to my risk of developing the disease, kept me vigilant about getting a yearly mammogram screening since I turned 32. The test never showed any suspicious lesions over the last nearly 2 decades,...
Consumption of Sugar-Sweetened Beverages May Raise Gastric Cancer Risk
Approximately 65% of U.S. adults report consuming one or more sugar-sweetened beverages every day. Researchers found that consuming these drinks daily was associated with an increased risk of developing gastric cancer, whereas consumption of artificially sweetened beverages was not associated with...
Electronic Prior Authorization Requirements for Drugs
The Association for Clinical Oncology (ASCO) submitted formal comments (see https://bit.ly/4xYRg1j) to the Centers for Medicare & Medicaid Services (CMS) in response to the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. If finalized, this rule will require...
High-Risk ERBB2-Negative Breast Cancer: Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy
The addition of dual PD-1 and LAG-3 inhibition with cemiplimab-rwlc and fianlimab to standard paclitaxel-based neoadjuvant chemotherapy resulted in improved pathologic complete response rates in patients with early-stage, high-risk ERBB2 (formerly HER2 or HER2/neu)-negative breast cancer, according ...
